ASMB
Assembly Biosciences, Inc.
ASMB's fundamentals are strong: revenue grew 80% and its operating margin improved to −32%, though free cash flow was negative. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ASMB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
ASMB's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
ASMB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $19.00 | -5.8% |
| Current | 20x | $20.18 | — |
| Fair | 124x | $124 | +513% |
| Expensive | 344x | $344 | +1604% |
Historical ranges are pointers, not guarantees.
ASMB's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
ASMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ASMB's losses to shrink, with revenue growing.
ASMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.00 | +$5.76 |
| Q2 2026 | $1.21 | +$6.76 |
| Q1 2026 | $0.08 | +$6.28 |
| Q4 2025 | -$0.55 | +$6.14 |
| Q3 2025 | -$4.76 | +$2.25 |
| Q2 2025 | -$5.55 | +$3.19 |
| Q1 2025 | -$6.20 | +$4.40 |
| Q4 2024 | -$6.69 | +$6.69 |
ASMB has returned to profit: it earned $1.00 per share over the past year, after losing money the year before.
ASMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3M | -73% |
| Q2 2026 | $13.4M | +39% |
| Q1 2026 | $8.2M | -13% |
| Q4 2025 | $42.5M | +477% |
| Q3 2025 | $10.8M | +58% |
| Q2 2025 | $9.6M | +13% |
| Q1 2025 | $9.4M | +63% |
| Q3 2021 | $6.3M | -82% |
ASMB's revenue is growing: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -792% | -691 points |
| Q2 2026 | -47% | +68 points |
| Q1 2026 | -138% | -33 points |
| Q4 2025 | 47% | +203 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -115% | +28 points |
| Q1 2025 | -106% | +80 points |
| Q4 2024 | -157% | N/A |
ASMB's operating margin was −792% last quarter, down 691 points from the same quarter a year ago, near the bottom of its range since 2019.
ASMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.3M | -$2.1M |
| Q2 2026 | -$15.5M | +$1.3M |
| Q1 2026 | -$22.1M | +$1.3M |
| Q4 2025 | $14.2M | +$14.6M |
| Q3 2025 | -$15.2M | +$69K |
| Q2 2025 | -$16.8M | +$358K |
| Q1 2025 | -$23.4M | -$5.1M |
| Q4 2024 | -$407K | -101% |
ASMB has burned cash in almost every quarter: −$41M over the past year, against −$56M the year before.
ASMB Net Leverage
ASMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
ASMB's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
ASMB PE vs Healthcare Sector
| Metric | ASMB | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 26x | 22% below |
| PE % | 26 | 29 | 3 pts below |
ASMB is trading at 20x earnings, a 22% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ASMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.3 | 5.3% below |
| 20 week MA | $26.1 | 23% below |
| 50 week MA | $27.8 | 27% below |
| 100 week MA | $23.4 | 14% below |
| 200 week MA | $18.4 | 9.9% above |
ASMB has fallen below most of its moving averages, though it's still 9.9% above its 200-week average.
ASMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $251.3 | $74.4 | -70% |
| 2021 | $74.4 | $27.2 | -63% |
| 2022 | $27.2 | $15.1 | -44% |
| 2023 | $15.1 | $9.84 | -35% |
| 2024 | $9.84 | $15.2 | +54% |
| 2025 | $15.2 | $33.6 | +122% |
| 2026 YTD | $33.6 | $20.2 | -40% |
ASMB's yearly returns have swung widely, from +122% in 2025 to −70% in 2020. It's down 40% so far in 2026.